Welcome to our dedicated page for Eagle Pharmaceut news (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on Eagle Pharmaceut stock.
Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) generates a steady flow of corporate, product and governance updates that are relevant to investors following EGRX news. As a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise, Eagle regularly issues press releases about its commercial portfolio, pipeline programs and capital structure decisions.
Company announcements describe a portfolio that includes PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO, as well as BYFAVO and BARHEMSYS historically commercialized through its wholly owned subsidiary Acacia Pharma Inc. News items have covered transactions such as a royalty purchase agreement to monetize BENDEKA royalties and the divestiture of the U.S. marketing authorization for Barhemsys (amisulpride) to LXO Group, with Eagle noting that proceeds would support ongoing operations and debt repayment.
Governance and capital markets developments are also a recurring theme in Eagle’s news flow. The company has reported on the adoption and amendment of a limited duration stockholder rights plan, changes to the plan’s purchase price and duration, and cooperation agreements with significant stockholders involving board appointments. In addition, Eagle issues updates on its annual meeting of stockholders, proxy material availability, and the release of audited and unaudited financial statements.
Investors monitoring EGRX news can use this page to follow Eagle’s disclosures on its oncology and critical care products, CNS/metabolic critical care pipeline, financing transactions, and corporate governance actions. Regularly reviewing these updates can help readers understand how Eagle describes the evolution of its product portfolio, pipeline priorities and capital structure over time.
Eagle Pharmaceuticals (EGRX) reported Q1 2022 financial results with substantial growth, achieving total revenue of $115.9 million, significantly up from $41.2 million in Q1 2021. The company posted a net income of $44.1 million, or $3.47 per basic share. Key drivers included sales of $34.3 million from vasopressin and $37.2 million from PEMFEXY™. Eagle is set to acquire Acacia Pharma Group, enhancing its product offerings. With cash and receivables totaling $176.4 million, the company is positioned for further growth and diversification.
Eagle Pharmaceuticals (EGRX) is set to announce its first quarter financial results for 2022 on May 9, 2022, before the market opens. The conference call, hosted by CEO Scott Tarriff and CFO Brian Cahill, will take place at 8:30 a.m. ET. Investors can access the call via a toll-free number or through a webcast available on the company's investor relations page. The call will also be archived for 30 days. Eagle Pharmaceuticals focuses on developing innovative medicines, boasting a diverse pipeline of products aimed at enhancing patient care.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced a settlement with Hospira regarding patents linked to BENDEKA. Hospira can market its product starting January 17, 2028, or sooner under specific conditions. The settlement follows previous litigation instances where Eagle's patents were upheld. Furthermore, Eagle has been granted U.S. Patent No. 11,103,483 for bendamustine formulations, expiring in January 2031. The agreement is pending review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Eagle Pharmaceuticals has proposed an acquisition of Acacia Pharma valued at approximately €94.7 million, equivalent to €0.90 per share, payable in cash and Eagle stock. The strategic buy aims to integrate two FDA-approved products, BARHEMSYS® and BYFAVO®, targeting a combined addressable market of $3.1 billion annually. Eagle anticipates substantial financial synergies, leveraging its specialized hospital-based salesforce for accelerated product uptake. The transaction is expected to close in late Q2 2022, pending shareholder and court approval, and is projected to be earnings-accretive in 2024.
Eagle Pharmaceuticals, Inc. (EGRX) reported a Q4 2021 net loss of $(0.48) per share, with FY 2021 loss at $(0.66) per share. Adjusted non-GAAP net income for Q4 was $0.87 per share, while FY 2021 adjusted income was $2.64 per share. Early Q1 2022 revenue is projected at $120-$130 million, with adjusted EPS of $3.80-$4.10. The company initiated shipments of vasopressin, a generic alternative to Vasostrict®, and launched PEMFEXY™, a novel treatment for lung cancer. A new drug application for Landiolol is expected in Q2 2022.
Eagle Pharmaceuticals, Inc. (EGRX) will release its 2021 fourth quarter and full year financial results on March 7, 2022, before market open. A conference call hosted by CEO Scott Tarriff and CFO Brian Cahill will occur at 8:30 a.m. ET. Investors can access a replay of the call for one week post-event, along with an archived webcast available for 30 days on Eagle's website. Eagle Pharmaceuticals is dedicated to developing innovative medicines, operating within research, development, and commercialization across multiple therapeutic areas.
Eagle Pharmaceuticals has launched PEMFEXY (pemetrexed for injection), a new treatment for nonsquamous non-small cell lung cancer and mesothelioma. Sales started today, following FDA approval and a settlement with Eli Lilly. The U.S. market for ALIMTA, a competitor, reached $1.2 billion in the past year. The company anticipates substantial revenue growth from PEMFEXY in 2022. With a unique J-code, PEMFEXY is positioned to benefit both patients and providers in the oncology market.
Eagle Pharmaceuticals (EGRX) announced that AOP Health is progressing with a New Drug Application (NDA) for Landiolol, targeting a short-term reduction in ventricular rate for supraventricular tachycardia. This follows a licensing agreement from August 2021. Landiolol, already available in Japan and Europe, is expected to fill a critical need in emergency care. It has strong patent protection and anticipated market exclusivity upon approval. The FDA's collaboration suggests positive momentum, aiming for NDA submission next quarter.
Eagle Pharmaceuticals (EGRX) announced the launch of vasopressin, a generic alternative to Vasostrict, starting today, backed by 180 days of marketing exclusivity. This product, indicated for adults with vasodilatory shock, holds significant market potential as U.S. sales of Vasostrict reached $890 million as of September 30, 2021. The FDA approved the abbreviated new drug application on December 15, 2021. With an experienced sales force and existing contracts, Eagle expects substantial revenue growth from this launch in 2022.
Eagle Pharmaceuticals (EGRX) has announced key developments for 2022, including the launch of its vasopressin product on January 17, 2022, which comes with 180 days of marketing exclusivity. The company also plans to launch PEMFEXY on February 1, 2022, targeting a U.S. market valued at $1.2 billion. Additional pipeline advancements include human studies for fulvestrant, NDA submission for Landiolol, and clinical trials for CAL02. Eagle expects significant revenue growth driven by these initiatives, alongside a strong balance sheet to support strategic decisions.